The diversity of tumor-associated macrophages presents a major challenge to the clinical translation of myeloid cell-targeting strategies. In this issue of Cancer Cell, Yagel et al.
and Mateus-Tique et al. demonstrate that IL-12 armored CAR T cells effectively target tumor-promoting macrophage populations and reset the microenvironment toward an anti-cancer mode.
Cancer Cell published a clinical update in Oncology on 05 Feb 2026.
The item focuses on Turn CAR T against TAMs.
Review the original article for the full source wording and details.